abstract |
The invention relates to a composition and method for the treatment of immunological diseases comprising substances that block the lymphotoxin-beta receptor and signal transduction through this receptor. Lymphotoxin-beta receptor blocking agents are useful for the treatment of lymphocyte-mediated immunological diseases, and in particular for inhibition of Th1 cell-mediated immune responses. The invention also relates to soluble forms of the extracellular domain of the lymphotoxin-beta receptor, which act as lymphotoxin-beta blocking agents, and to the use of antibodies directed both against the lymphotoxin-beta receptor and against its ligand and superficial lymphotoxin . These antibodies act as lymphotoxin-beta blocking agents. |